Chlamydia pneumoniae and Mycoplasma pneumoniae

Francesco Blasi, P. Tarsia, S. Aliberti, R. Cosentini, L. Allegra

Research output: Contribution to journalArticlepeer-review

Abstract

Mycoplasma. pneumoniae infection occurs worldwide and is the most common cause of community-acquired pneumonia (CAP) in 5- to 20-year-olds. The most reliable diagnostic test is the enzyme immunoassay, which allows immunoglobulin (Ig)G and IgM titration and presents 92% sensitivity and 95% specificity on paired samples. Potentially active drugs are tetracyclines, macrolides, ketolides, lincosamides, streptogamines, chloramphenicol, and fluoroquinolones. Chlamydia pneumoniae accounts for 6 to 20% of CAP cases, depending on several factors such as setting of the studied population, age group examined, and diagnostic methods used. The current gold standard for serological diagnosis of acute infection is microimmunofluorescence testing. Tetracyclines and erythromycin show good in vitro activity and so far have been the most commonly employed drugs in the treatment of C. pneumoniae infection. New macrolides, ketolides, and new fluoroquinolones are other potentially effective drugs.

Original languageEnglish
Pages (from-to)617-624
Number of pages8
JournalSeminars in Respiratory and Critical Care Medicine
Volume26
Issue number6
DOIs
Publication statusPublished - Dec 2005

Keywords

  • Atypical microorganisms
  • Chlamydia pneumoniae
  • Community-acquired pneumonia
  • Mycoplasma pneumoniae

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Critical Care

Fingerprint Dive into the research topics of 'Chlamydia pneumoniae and Mycoplasma pneumoniae'. Together they form a unique fingerprint.

Cite this